국립암센터 / 김태현*, 이근석, 심성훈
Background: Few studies of proton beam therapy (PBT) for patients with liver metastasis from breast cancer (LMBC) are available to date. The aim of the present study was to evaluate the clinical effectiveness of PBT for patients with LMBC.
Material and methods: Seventeen patients with LMBC treated with PBT were included in this study. The median prescribed dose of PBT was 66 GyE (range, 60-80) in 10 fractions, 5 times a week. In patients with LMBC receiving PBT, freedom from local progression (FFLP), progression-free survival (PFS), and overall survival (OS) rates were assessed.
Results: The median follow-up time was 34.2 months (range, 11.5-56.1). The median FFLP time was not yet reached, and the 3-year FFLP rates were 94.1% (95% confidence interval [CI], 82.9-105.3). The median times of PFS and OS were 7.9 months (95% CI, 5.3-10.5) and 39.3 months (95% CI, 33.2-51.9), respectively, and the 3-year PFS and OS rates were 19.6% (95% CI, -1.8-41.0) and 71.7% (95% CI, 46.8-96.6), respectively. Grade 3 or higher adverse events were not observed.
Conclusion: PBT for patients with LMBC showed promising FFLP and OS with safe toxicity profiles. These findings suggest that PBT can be considered a local treatment option in patients with LMBC.
Tae Hyun Kim 1 , Keun Seok Lee 2 , Sung Hoon Sim 2 , Yeon-Joo Kim 1 , Dae Yong Kim 1 , Heejung Chae 2 , Eun-Gyeong Lee 2 , Jai Hong Han 2 , So Youn Jung 2 , Seeyoun Lee 2 , Han Sung Kang 2 , Eun Sook Lee 2
1 Center for Proton Therapy, National Cancer Center, Goyang, South Korea.
2 Center for Breast Cancer, National Cancer Center, Goyang, South Korea.